THERAGENICS REPORTS 2ND QTR '05 NET LOSS OF $1 MILLION.

Theragenics Corporation(R) (NYSE: TGX), Buford, Geo., a provider of brachytherapy products that include TheraSeed(R), its premier palladium-103 prostate cancer treatment device, and wound closure products through its CP Medical product line, has announced financial results for the second quarter ended July 3, 2005. Revenues for the quarter were $11.4 million, which includes $2.1 million in revenues from our newly acquired subsidiary, CP Medical. Revenues, excluding CP Medical sales, were $9.3 million for the quarter, compared to $8.6 million in the same period last year, a 7.3% increase. This includes increases in both TheraSeed(R) and I-Seed products. For the half-year period, total revenues were $20.9 million, including CP Medical's sales. Excluding CP Medical sales, revenues in the six-month period were $18.8 million, compared to the prior year's $16.6 million, a 13.3% increase.

Net loss computed in accordance with generally accepted accounting principles in the U.S. (GAAP) for the quarter was $1.0 million, or $0.03 per share, compared to a net loss of $0.9 million, or $0.03 per share in the second quarter of 2004. For the half-year period, the GAAP net loss was $1.5 million, or $0.05 per share, compared to a net loss of $1.9 million, or $0.06 per share, in the comparable 2004 period. GAAP results for the second quarter of 2005 reflect $1.1 million of expenses, or $0.7 million after income tax effect, related to the previously disclosed investigation conducted under the direction of the Board of Directors and the separation of two executives from the company. On a non-GAAP basis, excluding these second quarter expenses, the net loss would have been $0.3 million, or $0.01 per share for the second quarter of 2005, and $0.8 million, or $0.03 per share for the first six months of 2005.

Commenting on the quarter, CEO and president M. Christine Jacobs stated, "We are pleased with the positive performance of both our core brachytherapy seed and wound closure businesses. Our brachytherapy seed revenues during the quarter showed improvement over the prior year, and we continue to be encouraged by the results from our direct sales force and our marketing campaigns. Although this quarter includes just eight weeks of results from CP Medical, we have experienced positive early results and believe that CP Medical has already begun to deliver on the promise of diversifying our product and revenue stream."

Theragenics Corporation(R) (NYSE: TGX) is a provider of brachytherapy and wound closure products. The Georgia-based medical device company manufacturers and markets its premier product, the palladium-103 TheraSeed(R) device (www.theraseed.com) and I-Seed, an iodine-125 device, which are used in the minimally invasive treatment of localized prostate cancer. Through its subsidiary, CP Medical (www.cpmedical.com), the company also manufactures and distributes medical products for diverse markets including wound closure and cardiac pacing, as well as the general, dental, cosmetic and veterinary surgery markets. The company is the world's largest producer of palladium-103. Theragenics continues to expand its legacy of delivering products that change lives for the better.

For more information, call 800/998-8479 or 770/271-0233 visit http://www.theragenics.com.